mrc

A series of kisspeptin peptide antagonists capable of suppressing GnRH and therefore steroid hormones. These can be useful in treating conditions such as prostate cancer, benign prostatic hyperplasia, endometriosis and uterine fibroids. The peptides may also have the potential to treat precocious puberty and polycystic ovarian syndrome. Kisspeptin is the ligand for GPCR54. It has a central role in control of GnRH secretion and therefore presents a new mode of action in the control of hormone dependant diseases. This series of peptides has demonstrated efficacy in various animal models reducing GnRH secretion, LH and testosterone secretion. Moreover, his is achieved by peripheral delivery of the peptides. Thus, these peptides could form the basis of new therapeutics in hormone dependant diseases. Opportunity 459

Rodent antibodies against CCR2 that markedly improved established disease in multiple sclerosis and rheumatoid arthritis animal models have been raised, and are now being humanised by MRC Technology. This novel approach to a well-characterised target uses IgG1 antibodies to CCR2 to deplete inflammatory monocytes without blocking CCR2 signalling, thus avoiding potential pro-inflammatory effects. Opportunity 333